多替阿巴拉米片中国什么时候上市？

(Triumeq) is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture of GlaxoSmithKline and Pfizer, based on the integrase inhibitor Tivicay (Dolutegravir) treatment plan also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. Dolutegravir tablets are suitable for adults and adolescents over 12 years old and weighing no less than 40kg. Since the ingredients in dolutegravir tablets may cause hypersensitivity reactions, regardless of the patient's race, before starting treatment with abacavir-containing products, they should be screened for HLA-B*5701 alleles. Today we are going to find out when Dota Abalami Tablets will be launched in China?

Dolutegravir tablets are a compound preparation. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50 mg, abacavir sulfate (calculated as abacavir) 600 mg and lamivudine 300 mg. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). Dolutegra abalami tablets were approved by the FDA on August 27, 2014. On January 20, 2018, ViiV, a joint venture of GlaxoSmithKline, the first complete antiviral treatment drug with dolutegravir (also known as DTG in English) as the core, dolutegravir tablets, was officially launched in China. This is also the first complete single-pill compound treatment plan in the field of HIV treatment in China.

This is the best-selling AIDS drug in the world in the past five years, and it is also an important part of GSK China in the field of AIDS in recent years. Since its approval for launch in 2014, the sales volume of Dolutegra abalami tablets has increased by leaps and bounds. In 2016, it ranked first in the global AIDS drug rankings, becoming GSK's best-performing business segment. 

Dolutegra abalamide tablets have the advantages of small drug dosage, low resistance to drug resistance, and low probability of drug side effects. This time, dolutegra abalamide tablets are based on DTG, an integrase inhibitor, as the core drug, and are combined with a treatment plan of two backbone drugs, abacavir and lamivudine, and are made into a single tablet for promotion, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

The above is the content of the listing, I hope it can help you!